Vascular thrombosis associated with antiphospholipide syndrome.
The aim of this study was to present our diagnostic and therapeutic experience with antiphospholipide syndrome (APS) and vascular thrombosis. Ninety-nine patients with positive antiphospholipide antibodies (aPL) and vascular thrombosis were included in the study: forty patients, according to clinical classification criteria, had primary antiphospholipide syndrome (PAPS), and fifty-nine patients had secondary antiphospholipide syndrome (SAPS). In PAPS group, 82.5% of the patients were LA-positive, 37.5% of the patients were IgG aCL-positive, 27.5% of the patients were IgM aCL-positive, and 15% of the patients were IgG antibeta2GPI-positive. In SAPS group, 61% of the patients were LA-positive, 50.8% of the patients were IgG aCL-positive, and 47.5% of the patients were IgM aCL-positive. Administered therapy was low molecular weight heparin (LMWH) throughout 7 days, followed by warfarin with prothrombin time maintained between 2.0 and 3.0 INR.
Glasnović
Marija
M
Department of Internal Medicine, School of Medicine, University J. J. Strossmayer, Osijek, Croatia. glasnovic.marija@kbo.hr
Bosnjak
Ivica
I
Vcev
Aleksandar
A
Soldo
Ivan
I
Bedeković
Drazen
D
Milaković
Sabina
S
Hecimović
Valentina
V
Horvatić
Elizabeta
E
Bardek
Mijo
M
D017153:Antibodies, Anticardiolipin / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000276:immunology; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D008875:Middle Aged; D013927:Thrombosis / Q000209:etiology* / Q000276:immunology
D017153:Antibodies, Anticardiolipin; D007136:Immunoglobulins; D016682:Lupus Coagulation Inhibitor